Understanding how the Kaposi's Sarcoma Herpesvirus Stays Hidden

KSHV Latent Infection Replication

NIH-funded research Brigham and Women's Hospital · NIH-11067849

This project aims to understand how the Kaposi's sarcoma herpesvirus (KSHV) hides and reproduces within cells, which is crucial for the growth of related cancers in people with weakened immune systems.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionBrigham and Women's Hospital NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-11067849 on NIH RePORTER

What this research studies

Kaposi's sarcoma herpesvirus (KSHV) causes several cancers, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease, especially in individuals with AIDS. Currently, there are no specific treatments for these conditions. This research focuses on how KSHV establishes a "latent" or dormant infection within cells, allowing it to persist and replicate its genetic material as cells divide. We want to learn more about the specific steps the virus takes to silence its active genes and how a key viral protein, LANA, helps the virus's genetic material copy itself and spread to new cells. Understanding these processes is vital because the survival of these cancer cells depends on the virus staying in this hidden state.

Who could benefit from this research

Good fit: This foundational research is for patients interested in the basic biology of KSHV-related cancers like Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease, particularly those with AIDS or weakened immune systems.

Not a fit: Patients seeking immediate new treatments or clinical trials would not directly benefit from this basic science project, as it focuses on understanding disease mechanisms rather than testing new therapies.

Why it matters

Potential benefit: If successful, this work could lead to new ways to target and disrupt the virus's ability to hide and grow, potentially offering new treatments for KSHV-associated cancers.

How similar studies have performed: While the specific mechanisms of KSHV latency are still being uncovered, other studies have shown that understanding viral persistence is a promising avenue for developing antiviral therapies.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency SyndromeAcquired Immunodeficiency SyndromeCancers
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.